KR920702854A - 제6위치에 트레오닌을 가지고 있는 소마토 스타틴의 옥타펩티드 유사물 - Google Patents

제6위치에 트레오닌을 가지고 있는 소마토 스타틴의 옥타펩티드 유사물

Info

Publication number
KR920702854A
KR920702854A KR1019910700860A KR910700860A KR920702854A KR 920702854 A KR920702854 A KR 920702854A KR 1019910700860 A KR1019910700860 A KR 1019910700860A KR 910700860 A KR910700860 A KR 910700860A KR 920702854 A KR920702854 A KR 920702854A
Authority
KR
South Korea
Prior art keywords
composition
alkyl
patient
compound
need
Prior art date
Application number
KR1019910700860A
Other languages
English (en)
Inventor
데이비드 에이취. 코이
윌리암 에이. 뮤어피
Original Assignee
원본미기재
더 어드미니스트레이터스 어브 더 툴레인 에듀케이셔널 펀드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 더 어드미니스트레이터스 어브 더 툴레인 에듀케이셔널 펀드 filed Critical 원본미기재
Publication of KR920702854A publication Critical patent/KR920702854A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/16—Somatostatin; related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

내용 없음

Description

제6위치에 트레오닌을 가지고 있는 소마토 스타틴의 옥타펩티드 유사물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 하기 일반식의 화합물 또는 그 약학적 허용염 ;
    상기 식에서, A1과 A2는 각각 H, C1-12알킬, C7-10페닐알킬, R1CO(여기에서, R1은 C1-20알킬, C3-20알케닐, C3-20알키닐, 페닐, 나프틸 또는 C7-10페닐알킬임)또는 R2OCO(여기에서 R2은 C1-20알킬, C7-10페닐알킬임)이며, 단 A1또는 A2중 하나가 R1CO 또는 R2OCO일 경우, 다른 하나는 H이어야만 하고, X1과 X2는 각각 H, F, Cl, Br, OH, CH3또는 CF3이며, 단 X1과 X2중 최소한 하나는 H이어야만하고, A3는 OH, NH2또는 NH-R3(여기에서 R3는 포화 지방족 C1-8알킬임)임.
  2. 제1항에 있어서, A1과 A2가 각각 H 또는 포화지방족 C1-3알킬이고, X1과 X2는 각각 H,F, Cl 또는 OH이며, 단 X1과 X2중 하나는 H이어야하고, R3가 포화지방족 C1-3알킬인 화합물 또는 그 약학적 허용염.
  3. 제2항에 있어서, 하기 식으로 표시되는 화합물 또는 그 약학적 허용염 :
  4. 제2항에 있어서, 하기 식으로 표시되는 화합물 또는 그 약학적 허용염 :
  5. 하기 식으로 표시되는 화합물 또는 그 약학적 허용염 :
    또는
  6. 치료학적 유효량의 제1항 또는 제5항의 화합물과 함께 약학적허용 담체 물질을 포함하는 GH, 표피성장인자, 인슐린, 글루카곤, 프로락틴, 췌장, 위 또는 소장으로 부터 분비되는 외분비물, 타키키닌 및 서브스턴스P(substance P)의 분비를 억제할 수 있는 치료조성물.
  7. 제6항에 있어서, GH의 분비를 억제할 수 있는 치료 조성물.
  8. 제6항에 있어서, 상기 조성물을 필요로 하는 환자에게 경구투여하기 위한 상기 액체, 알약, 정제, 또는 캡슐제 형태의 치료 조성물.
  9. 제6항에 있어서, 상기 조성물을 필요로 하는 환자의 피부에 적용하기 위한 크림, 겔, 로우션, 스프레이 또는 연고 형태의 조성물.
  10. 제6항에 있어서, 상기 조성물을 필요로 하는 환자에게 점적(drop) 또는 분무하여 비내(nasally)투여할 수 있는 억제 형태의 조성물.
  11. 제6항에 있어서, 상기 조성물을 필요로 하는 환자에게 정맥내, 피하, 비경구 도는 복강내 투여하기 위한 액제 형태의 조성물.
  12. 제6항에 있어서, 상기 조성물을 필요로 하는 환자에게 근육내 투여하기 위한 생물학적 분해 가능한 서방성 조성물 형태인 조성물.
  13. 제6항에 있어서, 친유기(lipophilic)염을 포함하고, 상기 조성물을 필요로 하는 환자에게 유성(oil)유제 또는 분산액의 형태로 투여하기 적당한 치료 조성물.
  14. 치료학적 유효량의 제1항 또는 제5항의 화합물을 GH, 표피 성장 인자, 인슐린, 글루카콘, 프로락틴, 췌장, 위 또는 소장에서 분비되는 외분비물, 타키키닌 및 서브스턴스 P를 감소시킬 필요가 없는 포유동물에게 투여하는 것을 특징으로 하는 포유동물의 치료방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910700860A 1989-12-08 1990-12-04 제6위치에 트레오닌을 가지고 있는 소마토 스타틴의 옥타펩티드 유사물 KR920702854A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44787689A 1989-12-08 1989-12-08
US447,876 1989-12-08
PCT/US1990/007074 WO1991009056A1 (en) 1989-12-08 1990-12-04 Octapeptide analogs of somatostatin having threonine at the sixth position

Publications (1)

Publication Number Publication Date
KR920702854A true KR920702854A (ko) 1992-10-28

Family

ID=23778103

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910700860A KR920702854A (ko) 1989-12-08 1990-12-04 제6위치에 트레오닌을 가지고 있는 소마토 스타틴의 옥타펩티드 유사물

Country Status (14)

Country Link
US (1) US5506339A (ko)
EP (1) EP0457888B1 (ko)
JP (1) JP2925321B2 (ko)
KR (1) KR920702854A (ko)
AT (1) ATE140237T1 (ko)
CA (1) CA2046594A1 (ko)
DE (1) DE69027767T2 (ko)
DK (1) DK0457888T3 (ko)
ES (1) ES2091907T3 (ko)
GR (1) GR3020513T3 (ko)
HU (1) HUT59166A (ko)
PT (1) PT96135B (ko)
WO (1) WO1991009056A1 (ko)
ZA (1) ZA909896B (ko)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU207104B (en) * 1991-01-25 1993-03-01 Biosignal Kutato Fejlesztoe Kf Process for producing new somatostatin analogs inhibiting tumour growth and pharmaceutical compositions comprising such compounds
US7238340B1 (en) * 1991-11-27 2007-07-03 Cis Bio International Monoamine, diamide, thiol-containing metal chelating agents
CA2079896A1 (en) * 1991-02-08 1992-08-09 Arthur E. Bogden Method of treating benign and malignant proliferative skin disease
US5411943A (en) * 1992-02-25 1995-05-02 Biomeasure, Inc. Hepatoma treatment with somatostatin analogs
US5871711A (en) * 1992-06-23 1999-02-16 Diatide, Inc. Radioactively-labeled somatostatin-derived peptides for imaging and therapeutic uses
US5716596A (en) * 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
ES2162822T3 (es) * 1992-07-27 2002-01-16 Univ Tulane Utilizacion de octapeptidos para el tratamiento de enfermedades asociadas con el receptor de neuromedina b.
US5569741A (en) * 1992-07-27 1996-10-29 Biomeasure, Inc. Cyclic octapeptide neuromedin B receptor antagonists
US5462926A (en) * 1992-07-27 1995-10-31 Biomeasure, Inc. Neuromedin B receptor antagonists which demonstrate selectivity
US5932189A (en) * 1994-07-29 1999-08-03 Diatech, Inc. Cyclic peptide somatostatin analogs
US5597894A (en) * 1995-06-05 1997-01-28 The Louisiana State University Medical Center Foundation Multi-tyrosinated somatostatin analogs
US5708135A (en) * 1995-09-29 1998-01-13 Biomeasure Incorporated Cyclic peptide analogs of somatostatin
US6262229B1 (en) 1996-12-04 2001-07-17 Biomeasure Incorporated Somatostatin antagonists
PT981363E (pt) 1997-05-13 2003-12-31 Conseils De Rec Appl Scient S Somatostatina e agonistas da somatostatina para reduzir o peso corporal
US6004928A (en) * 1997-05-13 1999-12-21 Biomeasure, Incorporated Method of treating hyperlipidemia
ES2216290T3 (es) * 1997-05-13 2004-10-16 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Somatostatina y agonistas de la somatostatina para el tratamiento de insensibilidad a la insulina y de sindrome x.
WO1998051330A1 (en) 1997-05-13 1998-11-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) Method and compositions for treating hyperlipidemia and other conditions
EP1291022A1 (en) * 1998-07-30 2003-03-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Methods of using lanreotide, a somatostatin analogue
IL140837A0 (en) * 1998-07-30 2002-02-10 Sod Conseils Rech Applic Method of using lanreotide, a somatostatin analogue
HUP0401535A3 (en) * 2001-03-08 2009-07-28 Univ Tulane Somatostatin antagonists and their use
MXPA03009048A (es) * 2001-04-09 2004-02-12 Univ Tulane Agonistas de la somatostatina.
CA2449634C (en) 2001-06-08 2011-08-02 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Somatostatin-dopamine chimeric analogs
EP2662087A1 (en) 2003-04-22 2013-11-13 Ipsen Pharma Somatostatin vectors
EP3473643A1 (en) 2008-06-12 2019-04-24 Ipsen Bioinnovation Limited Fusion proteins for use in the treatemnt of cancer
US20110171191A1 (en) 2008-06-12 2011-07-14 Syntaxin Limited Suppression of neuroendocrine diseases
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
JP6869720B2 (ja) 2013-06-13 2021-05-12 アンチセンス セラピューティクス リミテッド 併用療法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291022A (en) * 1975-03-11 1981-09-22 Sandoz Ltd. Organic compounds
CY1327A (en) * 1979-11-27 1986-06-27 Sandoz Ag Novel polypeptides,processes for their production,pharmaceutical compositions comprising said polypeptides and their use
US4328105A (en) * 1980-02-06 1982-05-04 Linde Aktiengesellschaft Treatment of suspended solids--and adsorbable contaminant--containing liquid
US4328135A (en) * 1980-06-13 1982-05-04 American Home Products Corporation Octapeptides lowering growth hormone
US4282143A (en) * 1980-06-13 1981-08-04 American Home Products Corporation Octapeptides lowering growth hormone
DK81082A (da) * 1981-03-06 1982-09-07 Sandoz Ag Fremgangsmaade til fremstilling af polypeptider
US4485101A (en) * 1983-10-11 1984-11-27 Administrators Of The Tulane Educational Fund Peptides
US4684620A (en) * 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
US4725577A (en) * 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
US4650787A (en) * 1985-04-25 1987-03-17 Schally Andrew Victor Biologically active octapeptides
US4904642A (en) * 1985-09-12 1990-02-27 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4853371A (en) * 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
JP2568228B2 (ja) * 1987-02-03 1996-12-25 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド 治療用ソマトスタチンアナログ
JP2809403B2 (ja) * 1987-07-07 1998-10-08 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド 治療用ソマトスタチンアナログ化合物
GB8813160D0 (en) * 1988-06-03 1988-07-06 Soc D Etudes Prod Chimique Therapeutic methods

Also Published As

Publication number Publication date
GR3020513T3 (en) 1996-10-31
JPH04505456A (ja) 1992-09-24
US5506339A (en) 1996-04-09
PT96135A (pt) 1991-09-30
EP0457888A4 (en) 1992-01-02
JP2925321B2 (ja) 1999-07-28
WO1991009056A1 (en) 1991-06-27
CA2046594A1 (en) 1991-06-09
ZA909896B (en) 1991-09-25
DE69027767D1 (de) 1996-08-14
HUT59166A (en) 1992-04-28
DE69027767T2 (de) 1997-01-02
DK0457888T3 (da) 1996-08-12
ATE140237T1 (de) 1996-07-15
PT96135B (pt) 1998-04-30
EP0457888A1 (en) 1991-11-27
ES2091907T3 (es) 1996-11-16
EP0457888B1 (en) 1996-07-10

Similar Documents

Publication Publication Date Title
KR920702854A (ko) 제6위치에 트레오닌을 가지고 있는 소마토 스타틴의 옥타펩티드 유사물
KR920700226A (ko) 선형 소마토스타틴 유사체
ES2526707T3 (es) Purificación y estabilización de péptidos y proteínas en agentes farmacéuticos
RU94033520A (ru) Впрыскиваемый лецитиновый гель
KR960700708A (ko) 3,4-디아릴크로만을 이용한 뼈 손실의 억제방법(methdos for inhibiting bone loss with 3,4-diarylchroman)
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
JP2008538547A (ja) 甲状腺刺激ホルモン放出ホルモン類縁体及び使用方法
JPS5513275A (en) Prodrug of non-steroid anti-inflammatory drug having improved absorption and anti-inflammatory drug composition comprising it
Plotnikoff et al. Oxotremorine antagonism by prolyl-leucyl-glycine-amide administered by different routes and with several anticholinergics
KR900003205A (ko) 제약 화합물
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
KR950000663A (ko) 트리테르펜 유도체 및 이를 함유하는 엔도텔린-수용체 길항물질
RU2002101622A (ru) Нафтохиноновые производные и их использование для лечения и борьбы с туберкулезом
KR920700227A (ko) 초고활성 인체 인슐린 동족체
FI956050A (fi) Biologisesti aktiiviset vasopressiinianalogit
RU98113920A (ru) Производные олигопептидов, содержащие d-алкилтриптофан и способные активировать высвобождение гормона роста
RU97107089A (ru) Полипептидные соединения, содержащие d-2-алкилтриптофан, стимулирующий высвобождение гормона роста
EP0647616A4 (en) COMPOUND BASED ON ZINC TRANEXAMATE.
NO20042100L (no) Fremgangsmate for administrering av et tymosinalfa 1-peptid
US5011824A (en) Rectal motilin preparation
GR3002765T3 (en) New pharmaceutical compositions for parenteral use containing a calcitonin as the active ingredient
EP0285367A2 (en) Pharmaceutical composition
Hall Clinical experiences with the sublingual administration of alpha estradiol
KR880004810A (ko) 소화성 궤양 치료제
CA1323301C (en) Thyrotropin-releasing hormone analogs in cns injury

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application